01354nam a2200265   4500001000800000005001700008007000300025008004100028040000800069041000800077100002500085245005500110300002500165520058600190650001200776650002600788650002600814650002700840650003700867650002900904650001700933650001900950650001600969773010300985ESSALUD20260902163508.0ta      t        pe ||||| |||| 00| 0 spa d  aBMG  aeng  aLundberg, Ingrid E.   aA Phase 3 Trial of brepocitinib in dermatomyositis  apáginas: 1953-1955  aDermatomyositis is a subgroup of idiopathic inflammatory myopathies — systemic autoimmune disorders that are typically characterized by the involvement of multiple organs, including muscle, skin, joints, lungs, gastrointestinal tract, and heart — all conditions with high morbidity and mortality. Treatment of myositis is based on off-label use of high doses of glucocorticoids, usually over long periods of time, in combination with immune-modulating agents and physical exercise. However, the outcome is often disappointing, with persisting inflammation and recurrent flares.  aALERGIA  aINMUNOLOGÍA GENERAL  aENFERMEDAD AUTOINMUNE  aDERMATOLOGÍA GENERAL  aENFERMEDAD PULMONAR INTERSTICIAL  aENFERMEDAD NEUROMUSCULAR  aNEUROLOGÍA  aNEUROCIRUGÍA  aCÉLULAS T0 022717dMassachusetts NEJM GroupoNEJM014tThe New England Journal of Medicine wESSALUDx0028-4793